REDWOOD CITY, Calif., May 17 /PRNewswire/ -- Pearl Therapeutics Inc., a company developing clinically differentiated doubleand triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, has been named a TiE50 Winner in the BioSciences category, as a leader in innovation, ingenuity and management excellence. The award was presented
"Each and every one of us at Pearl contributed to the receipt of this award," said Perry Karsen, president and chief executive officer at Pearl. "According to TiE, awards are granted to entrepreneurs that are risk-taking yet pragmatic, visionary but market-aware, with a passion to be the best. At Pearl, we strive to foster a culture that embodies these ideals, and I am proud to accept this award on behalf of the company and my colleagues."
Approximately 3,700 companies across five sectors (BioSciences, Cleantech, Internet, Software and Wireless) submitted applications or were nominated for a TiE50 award. In the BioSciences Sector, Pearl was one of about 400 companies from around the world with business models ranging from biotechnology, drug discovery, diagnostics, medical devices, services and drug development. TiE judges selected Pearl Therapeutics as one of only ten winners in the BioSciences category.
The Indus Entrepreneurs (TiE) and TiEcon
The Indus Entrepreneurs (TiE) is a global, not-for-profit, non-political, and non-religious organization dedicated to fostering entrepreneurs across its international network sponsored by top venture capital firms, and Fortune 500 corporations; spread across 53 chapters in 12 countries comprising 1,800 experienced entrepreneurs and business executives as charter members, and 12,000 aspiring entrepreneurs and professionals as members.
TiEcon is TiE's premier annual event and is the largest convention in the world dedicated to entrepreneurs. This year's event will host over 3,000 participants including entrepreneurs, venture capitalists, industry executives and thought leaders in the Santa Clara Convention Center from May 14 to 15, 2010.
About Pearl Therapeutics
Pearl Therapeutics is developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Leveraging its proprietary particle technology, formulation expertise and unparalleled product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals therapies that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics. The company's lead candidate, PT003, a fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI), is currently being studied in a Phase 2b clinical trial. Founded in 2006, Pearl Therapeutics is privately held and backed by Clarus Ventures, New Leaf Ventures and 5AM Ventures. For more information, please visit us at http://www.pearltherapeutics.com.
SOURCE Pearl Therapeutics Inc.
Subscribe to our Free Newsletters!
Niemann-Pick disease is a group of inherited metabolic disorders in which cholesterol and lipids ...